602 studies found for:    "melphalan"
Show Display Options
Rank Status Study
1 Active, not recruiting Busulfan Plus Melphalan Versus Melphalan
Condition: Myeloma
Interventions: Drug: Busulfan;   Drug: Melphalan;   Other: Questionnaire;   Drug: G-CSF;   Drug: High Dose Melphalan;   Procedure: Stem cell transplant
2 Unknown  Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
Conditions: Multiple Myeloma;   Newly Diagnosed Patients
Interventions: Drug: Melphalan;   Drug: Lenalidomide;   Drug: Prednisone
3 Terminated Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
Condition: Newly Diagnosed, Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: melphalan, prednisone;   Drug: melphalan, prednisone, thalidomide
4 Terminated Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: melphalan;   Drug: dexamethasone;   Drug: bortezomib
5 Active, not recruiting Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: amifostine trihydrate;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: bone marrow ablation with stem cell support
6 Terminated Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage
Condition: Retinoblastoma
Intervention: Drug: Melphalan
7 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
8 Active, not recruiting Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
9 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
10 Completed A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Interventions: Drug: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection;   Drug: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
11 Recruiting Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Condition: Multiple Myeloma
Intervention: Drug: busulfan, melphalan and fludarabine
12 Active, not recruiting Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib, Melphalan, Prednisone, Thalidomide;   Drug: Bortezomib, Melphalan, Prednisone
13 Completed Melphalan & Palifermin Followed by Peripheral Blood Stem Cell Transplant in Treating Pts w/Stage II-III Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Biological: palifermin;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation
14 Completed
Has Results
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: Melphalan;   Drug: Bortezomib;   Drug: Melphalan and bortezomib
15 Recruiting Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Drug: tacrolimus;   Drug: sirolimus
16 Active, not recruiting Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
17 Active, not recruiting Lenalidomide and High-Dose Melphalan
Conditions: Myeloma;   Stem Cell Transplantation
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Procedure: Stem Cell Infusion
18 Active, not recruiting Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Biological: therapeutic allogeneic lymphocytes
19 Recruiting Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
Condition: Regional Melanoma
Interventions: Drug: Melphalan;   Drug: Tropisetron;   Drug: Morphine
20 Not yet recruiting XM02 Filgrastim to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Interventions: Drug: XM02 filgrastim and high dose melphalan;   Drug: High dose melphalan;   Procedure: Autologous Stem Cell Transplant

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years